Frontiers in Cardiovascular Medicine

DECEMBER 18, 2024

Despite improvements in clinical outcomes of acute myocardial infarction (AMI), mortality rates remain high, indicating the need for further understanding of the pathogenesis and developing more effective cardiac protection strategies.

Myocardial Infarction 52

Myocardial Infarction Physiology Biomarkers Innovation 52

Frontiers in Cardiovascular Medicine

MARCH 30, 2025

This narrative review aims to evaluate strategies for reducing door-to-balloon (D2B) time in ST-elevation myocardial infarction (STEMI) patients, focusing on pre-hospital, in-hospital, and technological innovations, as well as addressing challenges to ensure sustainability.

Myocardial Infarction 52

Myocardial Infarction STEMI Innovation Technology 52

Frontiers in Cardiovascular Medicine

FEBRUARY 18, 2025

However, studies on diagnostic markers related to cellular senescence in acute myocardial infarction (AMI) have not been reported. IntroductionCellular senescence can cause heart failure.

Myocardial Infarction 52

Myocardial Infarction Heart Failure Research 52

Open Heart

MARCH 25, 2025

We aimed to determine the risk of myocardial infarction (MI) and stroke after BSI. Background Cardiovascular disease (CVD) events triggered by inflammation are an underappreciated and poorly quantified cause of morbidity and mortality in patients with bloodstream infections (BSIs).

Myocardial Infarction 52

Myocardial Infarction Stroke Strokes Cardiovascular Disease 52

Heart BMJ

MARCH 26, 2025

Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 However, mortality rate is greater in HF cases developing >3 days following MI compared with less than or equal to 3 days after MI.

Myocardial Infarction 52

Myocardial Infarction Preserved Ejection Fraction Heart Failure Aortic valve 52

Frontiers in Cardiovascular Medicine

JANUARY 23, 2025

Background Early prediction of heart failure (HF) after acute myocardial infarction (AMI) is essential for personalized treatment.

Myocardial Infarction 52

Myocardial Infarction Heart Failure Research Hospital 52

Open Heart

JANUARY 21, 2025

Background Atrial fibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both conditions. Whether the risks of outcomes differ according to temporal order of AF and AMI is unclear.

Myocardial Infarction 52

Myocardial Infarction Atrial Fibrillation Diet Cancer 52

Frontiers in Cardiovascular Medicine

FEBRUARY 24, 2025

ObjectiveThis study aimed to evaluate the correlation between aerobic exercise intensity based on the 6min walk test (6MWT) and the anaerobic threshold (AT)-based equivalent in patients with acute myocardial infarction (AMI).

Myocardial Infarction 52

Myocardial Infarction Exercise Hospital Research 52

Cardiovascular Diabetology

JANUARY 3, 2025

Yet, the impact of GLP-1RA treatment before ST-segment elevation myocardial infarction (STEMI) on. Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reduces cardiovascular events in type 2 diabetes.

Myocardial Infarction 115

Myocardial Infarction Diabetes STEMI Research 115

Frontiers in Cardiovascular Medicine

DECEMBER 3, 2024

However, whether immediate blood glucose and FIB levels affect coronary blood flow during primary percutaneous coronary intervention (PCI) remains unclear.ObjectiveTo explore the correlation between admission blood glucose (ABG), fibrinogen (FIB) and slow blood flow during primary PCI for acute ST segment elevation myocardial infarction (STEMI).MethodsA

Myocardial Infarction 52

Myocardial Infarction STEMI Risk Factors Hospital 52

Open Heart

FEBRUARY 17, 2025

Background Despite limited beneficial evidence, mechanical circulatory support (MCS) is commonly used in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS). In this Dutch registry, we investigated MCS usage, associated patient characteristics and clinical outcomes.

Cardiogenic Shock 52

Cardiogenic Shock Myocardial Infarction Aortic Outcomes 52

Heart BMJ

SEPTEMBER 25, 2024

In the beginning of the 20th century, the first reports of the clinical manifestations of myocardial infarction (MI) appeared, followed around a decade later by reports regarding the electrocardiographic (ECG) changes associated with MI ( figure 1 ).

Myocardial Infarction 98

Myocardial Infarction Document 98

The New England Journal of Medicine

FEBRUARY 12, 2025

In a randomized trial involving patients with acute myocardial infarction, colchicine did not decrease the risk of major adverse cardiovascular events over a median follow-up period of 3 years.

Myocardial Infarction 71

Myocardial Infarction 71

DAIC

JULY 10, 2024

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by CellProthera , as well as plans to continue the relationship into Phase III.

Myocardial Infarction 105

Myocardial Infarction Heart Failure Heart Attack Heart attacks 105

Open Heart

MARCH 28, 2025

The presence of atrial arrhythmias during stress testing at all time points was also associated with later diagnosis of coronary artery disease or myocardial infarction: OR 1.82 (95% CI 1.09, 3.03), p=0.02. However, it is linked to subsequent diagnosis of AF, coronary artery disease and myocardial infarction.

Arrhythmia 75

Arrhythmia Coronary Artery Disease Myocardial Infarction Atrial Fibrillation 75

HeartRhythm

DECEMBER 31, 2024

Curtain etal1 performed an analysis of the VALIANT (Valsartan in Acute Myocardial Infarction) and PARADISE-MI (Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) trials to evaluate whether risk of sudden cardiac arrest (SCA) following acute myocardial infarction (MI) has changed over time.

Cardiac Arrest 79

Cardiac Arrest ACE Inhibitor Myocardial Infarction Heart Failure 79

JAMA Cardiology

DECEMBER 19, 2023

This post hoc analysis of the Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) randomized clinical trial investigates the efficacy and safety of the de-escalation strategy of switching from ticagrelor to clopidogrel vs dual antiplatelet therapy with ticagrelor in stabilized patients with acute myocardial (..)

Myocardial Infarction 80

Myocardial Infarction 80

Circulation

FEBRUARY 13, 2025

The development of coronary care units is often credited for a dramatic decline in mortality rates after acute myocardial infarction throughout the 1960s. As the underlying patient population became progressively sicker, changes in organizational structure, staffing, care delivery, and training paradigms lagged.

Critical Care 72

Critical Care Myocardial Infarction Research Cardiovascular Disease 72

American College of Cardiology

OCTOBER 29, 2024

The goal of the CLEAR SYNERGY OASIS 9 trial was to determine the long-term cardiovascular (CV) effects of colchicine following percutaneous coronary intervention (PCI) for ST-segment elevation or large non–ST-segment elevation myocardial infarction (STEMI or NSTEMI, respectively).

Myocardial Infarction 67

Myocardial Infarction STEMI Article 67

Frontiers in Cardiovascular Medicine

DECEMBER 9, 2024

BackgroundMyocardial infarction(MI) is one of the most serious health threats.

Myocardial Infarction 52

Myocardial Infarction Research 52

American College of Cardiology

MARCH 4, 2024

Hemoglobin (Hb) threshold for red cell transfusion in myocardial infarction (MI) with anemia has been a matter of debate. Previous randomized trials have not consistently shown a benefit of liberal transfusion strategy.

Myocardial Infarction 68

Myocardial Infarction Article 68

Nature Reviews - Cardiology

MAY 2, 2024

Nature Reviews Cardiology, Published online: 03 May 2024; doi:10.1038/s41569-024-01031-z In the AEGIS-II trial, infusion of apolipoprotein A-I to increase cholesterol efflux capacity did not improve outcomes in patients with acute myocardial infarction.

Myocardial Infarction 64

Myocardial Infarction Cholesterol Outcomes 64

JAMA Cardiology

JUNE 17, 2024

This genetic association study evaluated genetic variants associated with increased risk of vasospastic angina.

Angina 104

Angina Myocardial Infarction 104

Frontiers in Cardiovascular Medicine

JANUARY 15, 2024

Background The diagnosis of a left ventricular (LV) thrombus in patients with ST-segment elevation myocardial infarction (STEMI) remains challenging. The aim of the current study is to characterize clinical predictors for LV thrombus formation, as detected by cardiac magnetic resonance imaging (CMRI). and 59%, respectively.

Myocardial Infarction 80

Myocardial Infarction STEMI Hospital 80

Cardiovascular Diabetology

MAY 26, 2024

Stress hyperglycemia, which is associated with poor prognosis in patients with acute myocardial infarction (AMI), can be determined using the stress hyperglycemia ratio (SHR). Impaired left ventricular functio.

Myocardial Infarction 78

Myocardial Infarction Research 78

The New England Journal of Medicine

MARCH 26, 2025

This feature about a man who had had a myocardial infarction with preserved left ventricular ejection fraction offers a case vignette accompanied by two essays, one supporting the use of beta-blockers after discharge and the other recommending no use of beta-blockers.

Myocardial Infarction 56

Myocardial Infarction 56

Cardiovascular Diabetology

JANUARY 17, 2025

The aim of this study was to investigate the difference between perceived and calculated diabetes risks among post-myocardial infarction (AMI) patients using the Finnish Diabetes Risk Score (FINDRISC).

Myocardial Infarction 64

Myocardial Infarction Diabetes Research 64

HCPLive

APRIL 12, 2024

Ankeet Bhatt, MD, MBA, discusses a NUDGE-FLU analysis from ACC.24 24 examining effect of the CV gain-framed nudge in patients with and without history of AMI.

Myocardial Infarction 119

Myocardial Infarction 119

American College of Cardiology

NOVEMBER 17, 2024

The goal of the CLEAR SYNERGY (OASIS 9) spironolactone trial was to determine the potential cardiovascular (CV) benefit of spironolactone following percutaneous coronary intervention (PCI) for ST-segment or large non–ST-segment elevation myocardial infarction (STEMI or NSTEMI, respectively) regardless of post-MI left ventricular ejection fraction (..)

Myocardial Infarction 53

Myocardial Infarction STEMI Article 53

Frontiers in Cardiovascular Medicine

OCTOBER 7, 2024

BackgroundCardiac rupture (CR) after acute myocardial infarction (AMI) is a fatal mechanical complication. The early identification of factors related to CR in high-risk cases may reduce mortality. and in-hospital mortality was approximately 57%.

Myocardial Infarction 59

Myocardial Infarction Risk Factors Hospital 59

American College of Cardiology

APRIL 7, 2024

The goal of the REDUCE-AMI trial was to evaluate the potential benefit of beta-blockade following acute myocardial infarction (AMI) in patients with preserved left ventricular ejection fraction (LVEF) in the modern era of coronary revascularization and medical therapy.

Myocardial Infarction 64

Myocardial Infarction Article 64

Med Page Today

JUNE 26, 2024

(MedPage Today) -- Influenza infection was associated with an increased risk of acute myocardial infarction (MI), especially for those without a prior hospitalization for coronary artery disease (CAD), according to a Dutch observational case series.

Heart Attack 143

Heart Attack Heart attacks Coronary Artery Disease Myocardial Infarction 143

Cardiovascular Diabetology

JANUARY 21, 2024

It is well-known that systemic inflammation plays a crucial role in the pathogenesis and prognosis of acute myocardial infarction (AMI). The systemic immune-inflammation index (SII, platelet × neutrophil/lymph.

Myocardial Infarction 72

Myocardial Infarction Diabetes Research 72

Frontiers in Cardiovascular Medicine

NOVEMBER 17, 2024

Multiple logistic regression and restricted cubic spline (RCS) analyses were conducted to assess both linear and nonlinear associations between WWI and myocardial infarction. Subgroup analyses and interaction tests were also performed.ResultsAmong the 31,535 participants analyzed, 1,449 (4.82%) had experienced a myocardial infarction.

Myocardial Infarction 59

Myocardial Infarction BMI Angina Obesity 59

Cardiovascular Diabetology

JANUARY 21, 2025

The impact of sodiumglucose cotransporter-2 (SGLT2) inhibitors on mortality following myocardial infarction (MI) remains uncertain. Additionally, the role of type 2 diabetes mellitus (T2DM) and heart failure.

Myocardial Infarction 64

Myocardial Infarction Heart Failure Diabetes Research 64

American College of Cardiology

JANUARY 23, 2024

Both the COMPLETE and PRAMI trial findings supported the benefits of complete revascularization over culprit-only percutaneous coronary intervention (PCI) in patients presenting with myocardial infarction (MI) and multivessel coronary artery disease.

Myocardial Infarction 69

Myocardial Infarction Coronary Artery Disease Article 69

Frontiers in Cardiovascular Medicine

FEBRUARY 13, 2025

Specific cardiovascular diseases, such as acute myocardial infarction, arrhythmias, pulmonary hypertension and pericarditis, were also pointed. SiO2 exposure was linked to an increased risk of myocardial infarction, with potential mechanisms involving inflammation and platelet activation.

Myocardial Infarction 52

Myocardial Infarction Biomarkers Pericarditis Cardiovascular Disease 52